Dopamine and social anxiety disorder

Revista Brasileira de Psiquiatria

Volumn 28, Issue 4, 2006, Pages 263-264

  Robinson, Hayley M ^a   Hood, Sean D ^a   Bell, Caroline J ^b   Nutt, David J ^c  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF OTAGO   (New Zealand)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE; MONOAMINE OXIDASE INHIBITOR; OLANZAPINE; SEROTONIN; TRICYCLIC ANTIDEPRESSANT AGENT;

ATYPICAL DEPRESSION; DISEASE ASSOCIATION; EDITORIAL; HUMAN; MENTAL DISEASE; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; SCHIZOPHRENIA; SOCIAL PHOBIA;

ANIMALS; ANXIETY DISORDERS; HUMANS; MODELS, NEUROLOGICAL; RECEPTORS, DOPAMINE D2; SOCIAL BEHAVIOR DISORDERS;

EID: 33846521633     PISSN: 15164446     EISSN: None     Source Type: Journal    
DOI: 10.1590/S1516-44462006000400003     Document Type: Editorial

References (5)

1. Willner P, Hale AS, Argyropoulos S. Dopaminergic mechanism of antidepressant action in depressed patients. J Affect Disord. 2005;86(1):37-45.
2. Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E. Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry. 1997;154(2):239-42.
3. Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M. Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry. 2000;157(3):457-9.
4. Basu N, Klenavic K, Gamberg M, O'Brien M, Evans D, Scheuhammer AM, Chan HM. Effects of mercury on neurochemical receptor-binding characteristics in wild mink. Environ Toxicol Chem. 2005;24(6):1444-50.
5. Barnett SD, Kramer ML, Casat CD, Connor KM, Davidson JR. Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol. 2002;16(4):365-8.